Promising new agents in the treatment of non-small cell lung cancer

Cancer Chemotherapy and Pharmacology
M J Edelman, D R Gandara

Abstract

A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

References

Feb 22, 1979·Nature·P B SchiffS B Horwitz
Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M FukuokaN Masuda
Feb 20, 1992·The New England Journal of Medicine·C Schaake-KoningA Nijs
Jan 1, 1992·Cancer Chemotherapy and Pharmacology·R L SouhamiP G Harper
Nov 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MasudaS Kishimoto
Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K S AlbainR B Livingston
Feb 20, 1991·Journal of the National Cancer Institute·I Ringel, S B Horwitz
Aug 1, 1990·Journal of the National Cancer Institute·E K RowinskyR C Donehower
Mar 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L AbbruzzeseM N Raber
Mar 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Y ShumR T Heelan
Jul 1, 1983·The Journal of Cell Biology·F CabralB R Brinkley
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MasudaT Yana
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E E VokesJ A Hohneker
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyR C Donehower
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F V FossellaB Glisson
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A FrancisR T Heelan
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F V FossellaS Benner
Jul 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E TomiakV Auzannet
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S B Kaye
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R P AbrattT A Rugg
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H AndersonH H Hansen
Mar 3, 1993·Journal of the National Cancer Institute·W K MurphyM N Raber
Feb 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T J LynchE Frei
Mar 16, 1994·Journal of the National Cancer Institute·D AbigergesD Gandia

❮ Previous
Next ❯

Citations

May 1, 1996·The Annals of Thoracic Surgery·M J EdelmanJ R Benfield
Feb 13, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·V RatanatharathornP Pattaranutaporn
Nov 27, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·C Manegold
Feb 13, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Martin J EdelmanL Austin Doyle
Mar 10, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T Le ChevalierJ Bérille
May 3, 2003·Journal of Experimental Therapeutics & Oncology·Carl W GilbertMark D Pegram
Nov 11, 2009·Journal of Cellular and Molecular Medicine·Wang RuiChen Long-Bang
Mar 10, 2004·Hematology/oncology Clinics of North America·Sakkaraiappan Ramalingam, Chandra P Belani
Feb 25, 1998·Japanese Journal of Cancer Research : Gann·T YamoriT Kadota
Jul 27, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·M A SeidmanP L Leopold
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R GandaraUNKNOWN Southwest Oncology Group
Aug 3, 2004·Cancer Gene Therapy·Eugene Lin, John Nemunaitis
Jan 11, 2003·Cancer Gene Therapy·John Nemunaitis, Jeffrey Edelman
May 2, 2003·Cancer Chemotherapy and Pharmacology·Philip C MackPaul H Gumerlock
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I MonnetE Cvitkovic
Aug 6, 2003·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·John Nemunaitis
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R GandaraC Belani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.